Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 16, Pages -Publisher
MDPI
DOI: 10.3390/jcm11164772
Keywords
birdshot chorioretinopathy; multimodal imaging; HLA-A-29; posterior uveitis; immunosuppressive treatment
Categories
Ask authors/readers for more resources
Birdshot chorioretinopathy is a bilateral chronic inflammation of the eye, primarily affecting middle-aged individuals of European descent. Recent advances have highlighted the role of Endoplasmic Reticulum Aminopeptidase 2 in disease pathogenesis. Multimodal imaging and visual field testing are valuable tools for diagnosis and monitoring. There is no consensus on optimal treatment, with long-term management often requiring immunosuppressive or biological therapies.
Birdshot chorioretinopathy (BSCR) is a bilateral chronic inflammation of the eye with no extraocular manifestations. BSCR affects middle-aged individuals from European descent and is strongly associated with the human leucocyte antigen (HLA)-A29 allele. The immune mechanisms involved are not fully understood, but recent advances have shown the role of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in disease pathogenesis. Multimodal imaging, including fluorescein angiography, indocyanine angiography, fundus autofluorescence, and optical coherence tomography, are useful in confirming the diagnosis and monitoring disease activity. Visual field testing is also important to assess the disease progression. To date, there is no consensus for optimal treatment regimen and duration. Local and systemic corticosteroids can be used for short periods, but immunosuppressive or biological therapies are usually needed for the long-term management of the disease. Here, we will review publications focused on birdshot chorioretinopathy to give an update on the pathophysiology, the multimodal imaging, and the treatment of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available